Latest News

ZEISS CLINIC 360 is an all-in-one cloud and browser-based software platform designed to consolidate ophthalmic diagnostic and medical record data into a single, unified patient view.

The FDA issued a recall notice for an eye drop designed to relieve ocular redness, itching, burning, and watery eyes. The Class II recall alerts consumers and physicians to possible temporary or reversible health effects, but serious harm is unlikely.

Neel S. Vaidya, MD, MPH, MBA, on why keratoconus can progress aggressively in children and teens—and how early topographic screening and prompt crosslinking protect long-term vision.

Researchers in the UK have developed a new treatment approach for aniridia-related keratopathy (ARK), a rare genetic ocular disease, namely, a collagen scaffold that delivers limbal epithelial stem cells and stromal stem cells to the area affected by ARK. The treatment resulted in improved ocular surface scores and visual acuities.

CMS payment rates for the FSYX Ocular Pressure Adjusting Pump take effect October 1, 2026, clearing a reimbursement path for the noninvasive glaucoma device.

AI accelerates retina trials and imaging insights, boosts screening access, and raises urgent questions on regulation, privacy, and equity.

AI model beats human graders at spotting glaucoma risk in UK population retinal photos, boosting accuracy and strengthening the case for scalable AI vision screening.

The Jack McGovern Coats' Disease Foundation has announced the initiation of new research to develop the first validated animal model of Coats' Disease, a rare eye disorder that primarily affects children.

Phase 3 DURAVYU insert misses key vision endpoint in wet AMD but cuts injections; pivotal LUCIA readout may decide its future.

Byron Lam, MD, and Benjamin Bakall, MD, PhD, discuss what an FDA approval of tinlarebant could mean for the Stargardt disease type 1 standard of care.

EyePoint has finished enrolling both pivotal Phase 3 trials evaluating its sustained-release intravitreal insert against aflibercept in diabetic macular edema, setting up a topline readout in late 2027.

Approach centers on pressure-free messaging and optometric education

Patient enrollment is complete in a phase 3 registrational, or pivotal, trial to evaluate OPGx-LCA5, a gene therapy that is under investigation for treating Leber congenital amaurosis type 5-associated inherited retinal disease.